美股异动｜礼来跌3.2%，美国FDA对其减肥药审批延期

Core Viewpoint - Eli Lilly (LLY.US) shares fell by 3.2%, closing at $1,038.69, following the announcement that the FDA has postponed its decision on the weight loss drug orforglipron to April 10, from the previously expected decision by the end of March [1]. Company Summary - Eli Lilly's stock experienced a decline of 3.2% [1]. - The FDA's decision regarding orforglipron, a weight loss medication, has been delayed to April 10 [1]. - The initial expectation was for the FDA to make a decision by the end of March [1].